|
Market Closed -
Other stock markets
|
After hours 04:00:00 | |||
| 92.71 USD | -1.50% |
|
91.85 | -0.93% |
| 06-29 | Abbott Laboratories Baby Formula Probe Dropped by DOJ After Years-Long Investigation Into Contamination Risks | MT |
| 06-29 | Global markets live: Verizon, Comcast, Apple, BT Group, Ipsen… |  |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 161,483 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -25.88% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 173,172 | 170,340 | 166,442 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -22.09% | -1.64% | -2.29% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 23.3x | 20x | 17.5x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.27x | 3.13x | 2.92x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | 3.39x | 1.2x | 1.2x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.21x | 2.95x | 2.75x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.45x | 3.11x | 2.84x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 12.9x | 11.7x | 10.4x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 14.8x | 13.1x | 11.6x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 20x | 18.1x | 16x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 5% | 5.53% | 6.24% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.547 | 2.715 | 2.866 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.75% | 2.93% | 3.09% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.976 | 4.634 | 5.288 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 64.1% | 58.6% | 54.2% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,261 | 54,766 | 58,667 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,388 | 14,551 | 15,928 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,665 | 13,038 | 14,362 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 7,018 | 8,389 | 9,226 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 11,689 | 8,857 | 4,959 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 92.71 | 92.71 | 92.71 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,741,813 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 23.32x | 3.45x | 12.94x | 2.75% | 161B | |
| 18.34x | 3.22x | 11.33x | 3.66% | 104B | |
| 15.48x | 0.18x | 11.12x | 0.84% | 54.8B | |
| 32.62x | 7.92x | 20.71x | 1.23% | 53.31B | |
| 38.67x | 3.06x | 10.49x | 2.48% | 42.76B | |
| 37.92x | 1.38x | 12.17x | 0.21% | 33.49B | |
| 28.59x | 5.09x | 16.23x | -.--% | 27B | |
| 42.12x | 7.3x | 26.34x | 0.25% | 25.06B | |
| 23.46x | 3.43x | 12.34x | 1.23% | 20.78B | |
| 19.86x | 2.74x | 10.67x | 1.59% | 20.47B | |
| Average | 28.04x | 3.78x | 14.43x | 1.42% | 54.27B | |
| Weighted average by Cap. | 25.61x | 3.59x | 13.64x | 2.05% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
